Abstract
Venous thromboembolism (VTE) represents one of the most important causes of morbidity and mortality in cancer patients. This investigation was undertaken to investigate the natural history of VTE in the oncology center in a tertiary care hospital. We did a retrospective study on cancer patients who presented to King Abdullah Medical city in Holly capital; a tertiary care hospital; from May 2011 to June 2013. Follow up period was calculated from time of VTE diagnosis till the last clinical visit or till patient death. Among 1,678 cancer patients, 132 (7.87 %) were diagnosed with VTE. The median patient age was 53.5 years, with female to male ratio 1.3/1. Thirty one patients (23.5 %) were diagnosed with VTE and cancer simultaneously, seventy four patients (56.1 %) were on chemotherapy and twenty eight patients (21.2 %) were on best supportive care.VTE were symptomatic in 110 patients (83.3 %) and asymptomatic in 22 patients (16.7 %). Lower limbs were the commonest site (42.4 %) with the highest incidence in patients with advanced stages (93 %). Forty nine (37 %) patients were receiving LMWH as prophylaxis. Median survival in months for patients with VTE prophylaxis versus without prophylactic, and asymptomatic versus symptomatic were (12.6 vs 6.3; p 0.12 and 9.8 vs 12.4; p 0.885, respectively). There is underutilization of thromboprophylaxis in our region, which needs more effort to reduce VTE burden. Also we need large prospective studies to clarify the impact of VTE symptoms and presentation on patient’s survival.
Similar content being viewed by others
References
Trousseau A (1865) Phlegmasia Alba dolens. In: Clinique Medicale d’Hotel-Dieu de Paris, vol 3 JB Balliere et Fils, Paris, p 654–812
Heit JA, O’Fallon WM, Petterson TM (2002) Relative impact of risk factors for deep veins and pulmonary embolism: a population-based study. Arch Intern Med 162:1245–1248
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population- based study. Arch Intern Med 158:585–593
Bick RL (2006) Cancer associated thrombosis: focus on extended therapy with delteparin. J Support Oncol 4:115–120
Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:2822–2829
Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Buller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104(5):1049–1054
Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119:60–68
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484–490
Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6:601–608
Khorana AA, Streiff MB, Farge D (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27:4919–4926
Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME (2006) Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17:297–303
Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 27:63–74
Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R (2009) Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 84:408–413
Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29:3466–3473
Singh R, Sousou T, Mohile S, Khorana AA (2010) High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 8:1879–1881
Palla A, Rossi G, Falaschi F, Marconi L, Pistolesi M, Prandoni P (2012) Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest 30:131–134
Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, DiPiro PJ, Nishino M (2011) Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer 117:3860–3866
Den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29:2405–2409
Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA (2011) Symptomatic and incidental thromboembolisms are both associated with mortality in pancreatic cancer. Thromb Haemost 106:371–378
Rashid ST, Thursz MR, Razvi NA, Voller R, Orchard T, Rashid ST, Shlebak AA (2005) Venous thromboprophylaxis in UK medical inpatients. J R Soc Med 98:507–512
Amin A, Stemkowski S, Lin J, Yang G (2008) Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol 6:910–920
Abba AA, Al Ghonaim MA, Rufai AM (2004) Physicians’ practice for prevention of venous thromboembolism in medical patients. J Coll Physicians Surg Pak 14:211–214
Sleiman Zade Asfahani WH, Taher AT, Al Rahawi D, Khalil I (2005) Venous thromboembolism in cancer patients referred to the American University of Beirut-Medical Center secondary to deep vein thrombosis; occurrence and risk factors. J Thromb Thrombolysis 20:179–182
Lyman GH, Khorana AA, Falanga A (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505
Gary HL, Alok AK, Nicole MK (2013) Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 49:1200–1218
Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, Lee YG, Cha Y, Kim YJ, Kim JH, Park DJ, Kim HH, Oh D, Lee JS (2010) The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 8(3):540–547
Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK (2010) The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 116(11):2596–2603
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850
Engelke C, Rummeny EJ, Marten K (2006) Pulmonary embolism at multi-detector row CT of chest: one year survival of treated and untreated patients. Radiology 239:563–575
Ethical Consideration
Ethical approval to conduct the study was taken from the IRB review committee before the commencement of the study.
Conflict of Interest
The authors certify that is no potential or actual conflict of interest related to this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mohammed, A.A., Al-Zahrani, A.S., Farooq, M.U. et al. Pattern of Venous Thrombosis in Cancer Patients: Frequency and Survival Effect; Single Center Experience. Indian J Hematol Blood Transfus 31, 439–445 (2015). https://doi.org/10.1007/s12288-014-0496-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-014-0496-8